Indapta Therapeutics, a biotechnology company focused on developing and commercializing a first-in-class, off-the-shelf, non-engineered, allogeneic G-NK (FcRγ-deficient Natural Killer) cell therapy to treat multiple cancers, and Lonza have entered a strategic partnership.   Under the terms of the agreement, Lonza will manufacture Indapta’s allogeneic G-NK cell therapy under current good manufacturing practices (cGMP) for use in clinical studies. Indapta will leverage Lonza’s process developmen...